Avrobio Plots Comeback With Early Data From Gaucher’s Gene Therapy

Sees Bluebird Success As Creating Pathway

Early data in Gaucher disease suggest Avrobio’s hematopoietic stem cell gene therapy could help patients who do not response to enzyme replacement therapy.

Avrobio
Avrobio is looking to revive its fortunes by developing a Gaucher's gene therapy. • Source: Shutterstock

More from Business

More from Scrip